The SARCO41 study suggests Lilly’s Verzenio could become the first targeted therapy for rare, aggressive tumour dedifferentiated liposarcoma.

Trials of AstraZeneca’s anselamimab and Regeneron’s Lynozyfic could deliver much-needed new therapeutic options for rare disease AL amyloidosis.

Millions of women with a breast cancer diagnosis could safely avoid chemotherapy that would not be effective, thanks to a genomics test.

Eli Lilly’s relentless pipeline-building drive has continued with a licensing deal for Hanmi’s sonefpeglutide, in phase 2 for short bowel syndrome.

Revolution Medicines’ pan-RAS(on) inhibitor daraxonrasib has delivered an unprecedented result in pancreatic cancer.